Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
11.01
-0.49 (-4.26%)
At close: Jul 17, 2026, 4:00 PM EDT
11.00
-0.01 (-0.09%)
After-hours: Jul 17, 2026, 4:10 PM EDT
Akari Therapeutics, Employees
As of December 31, 2025, Akari Therapeutics, had 6 total employees, including 5 full-time and 1 part-time employees. The number of employees decreased by 3 or -33.33% compared to the previous year.
Employees
6
Change (1Y)
-3
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$4,674,667
Market Cap
19.27M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 6 | -3 | -33.33% | 5 | 1 |
| Dec 31, 2024 | 9 | -3 | -25.00% | 8 | 1 |
| Dec 31, 2023 | 12 | -3 | -20.00% | 9 | 3 |
| Dec 31, 2022 | 15 | 6 | 66.67% | 15 | 0 |
| Dec 31, 2021 | 9 | 0 | - | 9 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| NextCure | 40 |
| Longeveron | 38 |
| Quince Therapeutics | 38 |
| Atossa Therapeutics | 16 |
| Lipocine | 14 |
| NewcelX | 12 |
| Cellectar Biosciences | 11 |
AKTX News
- 8 days ago - Akari Therapeutics, Registration statement: Registration filing - Filings
- 10 days ago - Akari Therapeutics, Registration statement: Registration filing - Filings
- 10 days ago - Akari Therapeutics (AKTX) Stock Rallies on a Scientific Advisory Board Addition - TipRanks
- 10 days ago - Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board - GlobeNewsWire
- 16 days ago - Akari Therapeutics, Registration statement: Registration filing - Filings
- 18 days ago - Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones - GlobeNewsWire
- 22 days ago - Akari Therapeutics, Registration statement: Registration filing - Filings
- 6 weeks ago - Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari's Differentiated PH1 Payload Platform Following ASCO 2026 - GlobeNewsWire